TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening)~* Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of \>= 20~* Clinical Global Impressions Scale-Severity (CGI-S) score of \>= 4~Exclusion Criteria:~* Clinical instability - 25% or greater increase/decrease in HAM-D 17 total score from screening to baseline~* Significant risk of suicide as assessed by clinician judgement, HAM-D 17 and Columbia Suicide-Severity Rating Scale scores Other eligibility criteria also apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine succinate sustained-release 25 mg (Type: EXPERIMENTAL): None
- Desvenlafaxine succinate sustained-release 50 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female healthy volunteer subjects, between 25 and 70 years of age, giving informed consent for facial laser ablation of the lower eyelid areas for the purpose of wrinkle removal.~* Lower eyelid skin is free of any irritation, scarring or dermatologic conditions which might interfere with the study.~* Willing and able to participate in the study and follow all study directions.~* Able to read, understand and sign the consent form prior to any study related procedures.~Exclusion Criteria:~* Female subjects who are pregnant, nursing, or planning a pregnancy during the course of the study, as determined by the interview and a urine pregnancy test.~* Presence of irritation or dermatologic skin conditions in the lower eyelid area.~* Known allergies to materials within the test formulations (i.e., yeast and/or yeast products).~* Use of topical or systemic drugs (corticosteroids, retinoids, immune modulators, immune suppressants, drugs with potential for contact dermatitis, drugs with potential for skin discoloration) that may have an effect on wound healing or may impact skin pigmentation.~* A history, upon wounding, of developing thickened scars, keloids, or excessive pigment change.~* An unstable or severe inter-current medical condition that, in the opinion of the investigator, might interfere with interpretation of study results or render the subject at high risk for treatment complications.~* Use of any investigational medication or device for any indication within 30 days of screening.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid
- 2 (Type: EXPERIMENTAL): GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid
- 3 (Type: EXPERIMENTAL): GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Femoral Tunnel and Clinical Outcome Using Two Anterior Cruciate Ligament Reconstruction Techniques

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Lachman test grade II,III and Pivot shift test grade II,III in physical examination~2. ACL rupture in MRI~3. Age 20\~60~4. within 6 months after trauma~Exclusion Criteria:~1. osteoarthritis (OA) change in X-ray~2. History of other ligament injury or ACL reconstruction in uninjured knee.~3. operation history of either ipsilateral or contralateral knee(fracture, etc)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Transportal (Type: EXPERIMENTAL): this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with transportal technique
- Outside in (Type: EXPERIMENTAL): this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with patients who underwent operation with outside in technique

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have been diagnosed with OAB symptoms at Visit 1 of this study. OAB is defined by the International Urogynecological Association (IUGA)/International Continence Society (ICS) 2010 joint report as urinary urgency, with or without urinary incontinence, usually with frequency and nocturia, with no proven infection or other obvious pathology.~* Patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment.~Exclusion Criteria:~* Patients who are currently taking Betmiga®.~* Contraindication(s) as per the Betmiga® Summary of Product Characteristics (SPC).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. OAB patients taking Betmiga® (Type: None): OAB patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Development of a Personalized, Real-time Intervention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~(a) between 18 and 25 years of age, (b) reported alcohol use at least 3x weekly over past month, (c) self-reported use of coping motive (mean of 2+ on coping subscale of MDMQ-R), (d) current anxiety and/or depression symptomatology (as assessed CES-D score of 16+ and GAD-7 scores 10+), (e) has access to a smartphone capable of receiving EMA and text, and access to email.~Exclusion Criteria:~(a) current DSM-5 diagnosis of moderate/severe other substance use disorder (i.e., other than alcohol), (b) a history of psychotic disorder or current psychotic symptoms, (c) current suicidal/homicidal ideation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- PFIcope+EMI (Type: EXPERIMENTAL): This will include: 1) an in-person personalized feedback session to present normative information and feedback on problems associated with drinking to cope, to discuss the individual's use of alcohol to cope, and to generate relapse prevention coping skills messages to be used in the EMI text intervention; 2) EMA to monitor affect and intention to drink after discharge; 3) tailored text messages (EMI) based on EMA responses (i.e., individualized coping skills messages when individuals report negative affect and intention to drink); and 4) additional EMA to monitor coping skills usage, alcohol use, and drinking to cope.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Jetstream G3™ Calcium Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient is ≥ 18 years of age.~2. Patient has claudication determined to be due to femoropopliteal lesion(s) requiring revascularization.~3. The target lesion(s) is/are located in the common femoral, superficial femoral or popliteal arteries.~4. The reference vessel lumen (proximal to target lesion) is ≥ 3.0mm.~5. The patient is an acceptable candidate for percutaneous intervention using the Jetstream G3 System in accordance with its labeled indications and instructions for use.~6. The patient has signed approved informed consent.~7. Moderate or severe vessel obstructive intraluminal calcification as demonstrated by IVUS and angiography.~Exclusion Criteria:~1. Patient has an uncontrollable allergy to nitinol, stainless steel or other stent materials or to contrast agent.~2. Patient is unable to take appropriate anti-platelet therapy.~3. Patient has no distal runoff vessels.~4. Deep wall calcium.~5. Interventional treatment is intended for in-stent restenosis at the peripheral vascular site.~6. Patient has target vessel with moderate or severe angulation (e.g., \>30 degrees) or tortuosity at the treatment segment.~7. Patient has a history of coagulopathy or hypercoagulable bleeding disorder.~8. Patient is receiving hemodialysis or has impaired renal function (creatinine is \> 2.5 mg/dl) at the time of treatment.~9. Patient has evidence of intracranial or gastrointestinal bleeding within the past 3 months.~10. Patient has had severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days.~11. Patient is pregnant or nursing a child.~12. Intended interventional treatment includes planned laser, brachytherapy or atherectomy procedure other than the Jetstream G3 System.~    -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Patients with PAD (Type: EXPERIMENTAL): Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention who have moderate to severe obstructive intraluminal calcium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 6-week Safety and PD Study in Adults With NAFLD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* BMI at least 28 kg/m2~* Type 2 diabetes and/or metabolic syndrome~Exclusion Criteria:~* Liver disease~* Type 1 diabetes~* Recent heart attack or stroke~* Inability to have an MRI scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- PF-06835919 Low Dose (Type: EXPERIMENTAL): 75 mg once daily
- PF-06835919 High Dose (Type: EXPERIMENTAL): 300 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with physician diagnosed chronic refractory cough (cough lasting \>8 weeks).~* \> 18 years of age~* Must be cognitively impaired~Exclusion Criteria:~* People with contraindications to MRI scanning (i.e. metal implants, claustrophobia).~* History of uncontrolled asthma or chronic respiratory disease (other than refractory cough).~* Evidence of an allergic reaction to capsaicin (chilli).~* Pregnant women.~* Smoking, current or recent history (last 6 months).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Chronic cough participant (Type: EXPERIMENTAL): Twenty-five (25) Idiopathic chronic cough patients, defined as refractory to disease modifying therapies (eg anti-asthma medications), will be recruited.~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of Adenosine Triphosphate (ATP; 0.2-300 milliM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo functional brain imaging (fMRI) for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin.
- Healthy control participant (Type: EXPERIMENTAL): Twenty-five (25) appropriately age and sex matched healthy non-smoking individuals will be recruited as the comparison group.~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of ATP (0.2-300 milliM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo fMRI for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Laxative Therapy With Lactulose in the Evolution of Organ Dysfunction in Critically Ill Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ICU patients expected to stay for 3 more days, on mechanical ventilation and receiving at least 20% of calculated nutrient intake enterally.~Exclusion Criteria:~* younger than 18 years,~* pregnancy,~* contraindication to enteral nutrition,~* patients with liver disease,~* contraindications to the use of lactulose,~* patients with poor prognosis or without full therapeutic indication investment,~* presence of colostomy or ileostomy,~* intestinal diseases,~* such as disease Crohn's,~* ulcerative colitis,~* short bowel syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lactulone (Type: EXPERIMENTAL): Patients receiving lactulone
- Control (Type: ACTIVE_COMPARATOR): Observational group. Compare to lactulone group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients with proven advanced and progressive RCC of the clear cell type~* Presence of RECIST v.1.1 evaluable lesions, all \< 5 cm~* Performance status: Karnofsky \> 70 %~* Laboratory values: • White blood cells (WBC) \> 3.5 x 109/l • Platelet count \> 150 x 109/l • Hemoglobin \> 6 mmol/l • Total bilirubin \< 2 x upper limit of normal (ULN) • ASAT, ALAT \< 3 x ULN (\< 5 x ULN if liver metastases present) • MDRD ≥ 40 ml/min~* Negative pregnancy test for women of childbearing potential (urine or serum)~* Age over 18 years~* Written informed consent~Exclusion criteria:~* Known or suspected CNS metastases including leptomeningeal metastases. History or clinical evidence of (CNS) metastases (unless they are previously-treated CNS metastases and patients meet all 3 of the following criteria: are asymptomatic, have had no evidence of active CNS metastases for ≥3 months prior to enrollment, and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days)~* Untreated hypercalcemia~* Chemotherapy, external beam radiation, immunotherapy or angiogenesis inhibitors or mTOR inhibitors within 4 weeks prior to study. Limited field external beam radiotherapy to prevent pathological fractures is allowed , when unirradiated, evaluable lesions elsewhere are present.~* Cardiac disease with New York Heart Association classification of III or IV~* Patients who are pregnant, nursing or of reproductive potential and are not practicing an effective method of contraception~* Any unrelated illness, e.g. active infection, inflammation, medical condition or laboratory abnormalities, which in the judgment of the investigator will significantly affect patients' clinical status~* Life expectancy shorter than 4 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lu-177-DOTA-girentuximab (Type: EXPERIMENTAL): Patients in receive 10 mg of girentuximab coupled to DOTA and labeled with 65 mCi/m2 of Lu-177 if targeting of In-111-DOTA-girentuximab is observed in at least 1 lesion. Patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chest radiograph or computed tomography scan of the thorax not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease in the opinion of the principal investigator or the sub-investigator.~* Chronic cough for ≥ 4 months and a diagnosis of refractory or unexplained chronic cough.~* Persistent cough, despite treatment in accordance with the latest guideline of cough from the Japanese Respiratory Society, cough is a burden to the participant, and needs further treatment.~* If female, is not pregnant, not breast-feeding, and either is not a woman of childbearing potential or agrees to follow the contraceptive guidance.~Exclusion Criteria:~* Current smoker, or has given up smoking within 12 months of Screening.~* History of upper or lower respiratory tract infection or recent clinically significant change in pulmonary status.~* Has a history of chronic bronchitis.~* Current use of an angiotensin converting enzyme inhibitor (ACEI) or has taken an ACEI within 3 months of Screening.~* Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m\^2 OR ≥30 mL/min/1.73 m\^2 and \<50 mL/min/1.73 m\^2 at Visit 1 with unstable renal function (defined as a ≥50% increase of serum creatinine compared to a value obtained at least 6 months prior to Visit 1).~* History of malignancy ≤ 5 years.~* User of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence.~* Systolic blood pressure \>160 mm Hg or a diastolic blood pressure \>90 mm Hg at Screening.~* History of cutaneous adverse drug reaction to sulfonamide antibiotics or other sulfonamide-containing drugs.~* Known allergy/sensitivity or contraindication to gefapixant.~* Donated or lost ≥1 unit of blood within 8 weeks prior to the first dose of gefapixant.~* Previously received gefapixant or is currently participating in or has participated in an interventional clinical study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gefapixant 15 mg BID (Type: EXPERIMENTAL): Participants will receive gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg twice daily (BID) during the study period (52 weeks).
- Gefapixant 45 mg BID (Type: EXPERIMENTAL): Participants will receive gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the study period (52 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete